Clinical Trial Update: Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing morning versus evening dosing of roflumilast in adults with stable asthma evaluates efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Daxas (roflumilast)
• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED